Dr Isaac Garcia-Murillas is a Translational Senior Scientific Officer at Professor Nick Turner’s Molecular Oncology group at the Institute of Cancer Research (ICR) where he focuses in the clinical utility of ctDNA as a biomarker to quantify minimal residual disease, monitor response to treatment and identify the emergence of drug resistance.
During the past years, interest in the use of circulating tumour DNA (ctDNA) as a non-invasive cancer biomarker has grown rapidly. Improvements in the genomic and molecular methods employed for ctDNA analysis are expanding the range of its potential applications, both in research settings and as a tool with clinical utility for cancer management. Several studies have demonstrated the attainability of ctDNA analysis to monitor response to treatment, assess the emergence of drug resistance and quantify minimal residual disease. In order to drive the implementation of ctDNA in personalized oncology and in cancer research several challenges remain to be circumvented.
During this webcast you will learn/our speaker will address:
- Technical challenges for clinical utility of liquid biopsy
- ctDNA as a biomarker in breast cancer
- dPCR for the detection of mutations on ctDNA
- Understanding Multicolour dPCR